Which has preferable valuation and earnings, TLX or AVTX?

Telix Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.03 -$7.12M N/A N/A Avalo Therapeutics $60K 11,924.63 -$78.26M -$5.46 N/A

Is TLX or AVTX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Avalo Therapeutics N/A -97.54% -72.42%

Is AVTX or DNLI more profitable?

Denali Therapeutics' return on equity of -52.20% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -97.54% -72.42% Denali Therapeutics N/A -52.20% -43.86%

Avalo Therapeutics (AVTX) Competitors

$13.61 -0.13 (-0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$13.69 +0.08 (+0.62%)

As of 05:21 PM Eastern

Compare

AVTX vs. TLX, DNLI, RCUS, BEAM, and TNGX

Should you buy Avalo Therapeutics stock or one of its competitors? MarketBeat compares Avalo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalo Therapeutics include Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), Arcus Biosciences (RCUS), Beam Therapeutics (BEAM), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Avalo Therapeutics (NASDAQ:AVTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Telix Pharmaceuticals has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 4 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 0 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.89 beat Telix Pharmaceuticals' score of 0.45 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Telix Pharmaceuticals	Neutral
Avalo Therapeutics	Very Positive

Telix Pharmaceuticals currently has a consensus price target of $21.13, indicating a potential upside of 121.44%. Avalo Therapeutics has a consensus price target of $48.13, indicating a potential upside of 253.60%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Telix Pharmaceuticals' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Avalo Therapeutics	N/A	-97.54%	-72.42%

Telix Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.03	-$7.12M	N/A	N/A
Avalo Therapeutics	$60K	11,924.63	-$78.26M	-$5.46	N/A

Summary

Avalo Therapeutics beats Telix Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Avalo Therapeutics compare to Denali Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Avalo Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	11,924.63	-$78.26M	-$5.46	N/A
Denali Therapeutics	$330.53M	9.67	-$512.54M	-$2.88	N/A

Avalo Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Avalo Therapeutics currently has a consensus price target of $48.13, indicating a potential upside of 253.60%. Denali Therapeutics has a consensus price target of $34.25, indicating a potential upside of 70.06%. Given Avalo Therapeutics' higher possible upside, research analysts clearly believe Avalo Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, Denali Therapeutics had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 2 mentions for Denali Therapeutics and 0 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.89 beat Denali Therapeutics' score of 0.76 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Avalo Therapeutics	Very Positive
Denali Therapeutics	Positive

Denali Therapeutics' return on equity of -52.20% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Denali Therapeutics	N/A	-52.20%	-43.86%

Summary

Denali Therapeutics beats Avalo Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Avalo Therapeutics (NASDAQ:AVTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

In the previous week, Arcus Biosciences had 5 more articles in the media than Avalo Therapeutics. MarketBeat recorded 5 mentions for Arcus Biosciences and 0 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.89 beat Arcus Biosciences' score of 0.09 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Arcus Biosciences	Neutral
Avalo Therapeutics	Very Positive

Avalo Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.64	-$353M	-$3.18	N/A
Avalo Therapeutics	$60K	11,924.63	-$78.26M	-$5.46	N/A

Arcus Biosciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arcus Biosciences currently has a consensus price target of $35.10, indicating a potential upside of 41.36%. Avalo Therapeutics has a consensus price target of $48.13, indicating a potential upside of 253.60%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Avalo Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Avalo Therapeutics	N/A	-97.54%	-72.42%

Summary

Arcus Biosciences and Avalo Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to Beam Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Avalo Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Avalo Therapeutics has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	11,924.63	-$78.26M	-$5.46	N/A
Beam Therapeutics	$139.74M	24.18	-$79.99M	-$0.68	N/A

Avalo Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

Avalo Therapeutics currently has a consensus target price of $48.13, indicating a potential upside of 253.60%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 42.61%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Beam Therapeutics had 4 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for Beam Therapeutics and 0 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.89 beat Beam Therapeutics' score of 0.93 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Avalo Therapeutics	Very Positive
Beam Therapeutics	Positive

Summary

Avalo Therapeutics beats Beam Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Avalo Therapeutics compare to Tango Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Avalo Therapeutics presently has a consensus price target of $48.13, indicating a potential upside of 253.60%. Tango Therapeutics has a consensus price target of $32.27, indicating a potential upside of 45.70%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Avalo Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Avalo Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Avalo Therapeutics has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	11,924.63	-$78.26M	-$5.46	N/A
Tango Therapeutics	$62.38M	51.36	-$101.59M	-$0.83	N/A

In the previous week, Tango Therapeutics had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 3 mentions for Tango Therapeutics and 0 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.89 beat Tango Therapeutics' score of 0.42 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Avalo Therapeutics	Very Positive
Tango Therapeutics	Neutral

Summary

Avalo Therapeutics beats Tango Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Avalo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTX vs. The Competition

Export

Metric	Avalo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$715.48M	$2.97B	$6.44B	$12.46B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-2.49	18.12	23.87	24.36
Price / Sales	11,924.63	303.59	521.52	117.07
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	3.03	3.95	9.99	6.73
Net Income	-$78.26M	$75.85M	$3.56B	$337.03M
7 Day Performance	-15.62%	-1.13%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	212.87%	23.03%	28.77%	33.98%

Avalo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTX Avalo Therapeutics	3.7161 of 5 stars	$13.61 -0.9%	$48.13 +253.6%	+212.3%	$715.48M	$60K	N/A	40	Positive News
TLX Telix Pharmaceuticals	4.5397 of 5 stars	$9.57 +1.1%	$21.13 +120.7%	-48.3%	$3.21B	$803.79M	N/A	1,184	Gap Up
DNLI Denali Therapeutics	3.5516 of 5 stars	$19.38 +4.0%	$34.25 +76.7%	+41.1%	$2.96B	N/A	N/A	430
RCUS Arcus Biosciences	2.7408 of 5 stars	$24.17 +3.2%	$33.89 +40.2%	+138.1%	$2.95B	$247M	N/A	500	Analyst Forecast
BEAM Beam Therapeutics	2.1697 of 5 stars	$29.79 +4.0%	$46.83 +57.2%	+75.1%	$2.95B	$139.74M	N/A	510

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalo Therapeutics (AVTX) Competitors

AVTX vs. TLX, DNLI, RCUS, BEAM, and TNGX

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Avalo Therapeutics compare to Denali Therapeutics?

Summary

How does Avalo Therapeutics compare to Arcus Biosciences?

Summary

How does Avalo Therapeutics compare to Beam Therapeutics?

Summary

How does Avalo Therapeutics compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalo Therapeutics (AVTX) Competitors

AVTX vs. TLX, DNLI, RCUS, BEAM, and TNGX

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Do insiders & institutionals hold more shares of TLX or AVTX?

Which has more volatility and risk, TLX or AVTX?

Does the media prefer TLX or AVTX?

Do analysts prefer TLX or AVTX?

Is TLX or AVTX more profitable?

Which has preferable valuation and earnings, TLX or AVTX?

Summary

How does Avalo Therapeutics compare to Denali Therapeutics?

Which has better valuation and earnings, AVTX or DNLI?

Which has more risk and volatility, AVTX or DNLI?

Do institutionals and insiders believe in AVTX or DNLI?

Do analysts rate AVTX or DNLI?

Does the media favor AVTX or DNLI?

Is AVTX or DNLI more profitable?

Summary

How does Avalo Therapeutics compare to Arcus Biosciences?

Does the media prefer RCUS or AVTX?

Which has higher valuation & earnings, RCUS or AVTX?

Which has more risk and volatility, RCUS or AVTX?

Do institutionals & insiders hold more shares of RCUS or AVTX?

Do analysts prefer RCUS or AVTX?

Is RCUS or AVTX more profitable?

Summary

How does Avalo Therapeutics compare to Beam Therapeutics?

Is AVTX or BEAM more profitable?

Which has stronger valuation & earnings, AVTX or BEAM?

Which has more volatility & risk, AVTX or BEAM?

Do analysts recommend AVTX or BEAM?

Do insiders & institutionals believe in AVTX or BEAM?

Does the media favor AVTX or BEAM?

Summary

How does Avalo Therapeutics compare to Tango Therapeutics?

Do analysts prefer AVTX or TNGX?

Is AVTX or TNGX more profitable?

Which has more risk & volatility, AVTX or TNGX?

Do insiders and institutionals hold more shares of AVTX or TNGX?

Which has stronger earnings & valuation, AVTX or TNGX?

Does the media favor AVTX or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools